Extracellular Domain Protein (ECD)

DIMA Biotechnology offers over 800 ECD proteins covering more than 600 single pass membrane protein targets. All the proteins were made using HEK293 mammalian cell secretion expression system to ensure the close-to-native structures and post-translational modifications of the target proteins. We also implemented a strict quality control process, including purity testing, antibody-drug interaction verification, freezing and thawing tests, thermal stability tests, etc. 

Applications:

  • Immunogens for antibody drug development
  • Reagents used for CAR-T positive cell monitoring
  • Reagents for antibody screening and functional testing
  • Reagents for antibody affinity measurement
Add Any content here
protein
Immune checkpoint proteins

Immune checkpoints are a class of proteins that regulate tumor immune microenvironment.

They can be classified into two categories, costimulatory immune checkpoints, such as OX40, GITR, ICOS, etc.; and co-suppressive immune checkpoints, such as PD1, CTLA-4, etc.

Right now there are a number of FDA approved drugs on co-suppressive targets, such as Yervoy, anti-CTLA-4 monoclonal antibody, Keytruda, anti-PD-1 monoclonal antibody and Tecentriq, anti-PD-L1 monoclonal antibody.

pages-416107bc534d939 1
Hematological cancer targets

DIMA Biotechnology LTD provide a full spectrum of functional proteins of new CAR T-cell targets.

All the proteins were made by using HEK293 mammalian cell secretion expression system and we implemented a strict quality control process, including purity testing, antibody-drug interaction verification, freezing and thawing Tests, thermal stability tests, etc.

pages-cvsdvdfffffb 1
Solid tumor targets

In recent years, the biopharmaceutical market is growing rapidly.

Compared with small molecule drugs, antibody drugs exhibit higher specificity and selectivity.

Therefore, it showed tremendous progresses in the treatment of hematological cancers and autoimmune diseases.

Due to complex tumor immune microenvironment, the development of therapeutic antibody drugs for solid tumor is more challenging.